A study published in Blood Advances found that the F8 genotype and higher factor dose are risk factors for developing inhibitors in patients with severe hemophilia A. The PUPs A-LONG study evaluated the safety and efficacy of efmoroctocog alfa in previously untreated patients with severe hemophilia A, showing an incidence of inhibitor development of approximately 31.1%. Further analyses revealed that certain F8 variants increased the risk of inhibitor development, while higher doses of treatment in patients with low-titer inhibitors could lead to progression into high-titer inhibitors. The study also suggested the need for exploration into the relationship between central venous access devices and hemophilia severity.
Source link
Genetics and Factor Dose Influence Inhibitor Development in Hemophilia A
